Company
Mesoblast
ASX:MSB / NASDAQ:MESO
First FDA-approved MSC product (Ryoncil).
At a glance
- Listing
- ASX:MSB / NASDAQ:MESO
- Category
- ASX listed
- Headquarters
- Melbourne
- Market cap
- ~A$2.6–2.8B
Thesis
Why it is in this universe
- Category
- ASX listed
- Market
- Australia
- Recent inflection
- Apr 2026 FDA IND clearance for Ryoncil in Duchenne MD; Ryoncil Y1 revenue ~US$100M.
- Services
- None recorded
- People tracked
- 2
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | ASX |
| Ticker | ASX:MSB / NASDAQ:MESO |
| Secondary listing | NASDAQ |
| Market cap | ~A$2.6–2.8B |
| Status | Listed and trading |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- Melbourne
- Website
- No site on file
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
People
Who variis tracks here (2)
variis does not publish portraits of named individuals without a licence to do so.
Recent inflection
What moved lately
Apr 2026 FDA IND clearance for Ryoncil in Duchenne MD; Ryoncil Y1 revenue ~US$100M.
Coverage
More on Mesoblast.
Sources
What this profile is built on
No source is on file for this company yet. Treat everything above as unverified until one is.
Every entity profile on variis is sourced. Not investment advice.